BRD4-IN-12

Overview

BRD4-IN-12 is a potent and orally active BRD4 inhibitor with an IC 50 of 7.9 nM. BRD4-IN-12 downregulates the expression of c-MYC , BCL-2 , CDK4 and upregulates p21 . BRD4-IN-12 inhibits tumor cell proliferation and promotes apoptosis . BRD4-IN-12 exhibits excellent antitumor effects in the HCT-116 colorectal cancer xenograft model. BRD4-IN-12 can be used for the study of colorectal cancer (CRC).

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Cytoskeleton | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Epigenetic Reader Domain | Products > Signaling Pathways > c-Myc | Products > Signaling Pathways > Bcl-2 Family | Products > Signaling Pathways > PAK

Product Information

• Catalog No.: HY-181505
• CAS No.: 3112325-99-9
• Molecular Formula: C21H24N4O4S
• Molecular Weight: 428.50
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source